# A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

> **NCT00735267** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 468 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** PD 0332334

## Key facts

- **NCT ID:** NCT00735267
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 468 (ACTUAL)
- **Why stopped:** Please see Detailed Description for termination reason.
- **Last updated:** 2012-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735267, "A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00735267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*